Aldagen, Inc., a pioneering biotechnology firm headquartered in the United States, is at the forefront of regenerative medicine. Founded in 2007, the company has made significant strides in developing innovative cell therapies, particularly focusing on the unique properties of adult stem cells. With operational regions extending across North America, Aldagen is dedicated to advancing treatments for various degenerative diseases and injuries. The company’s core offerings include proprietary stem cell products that harness the regenerative potential of adult stem cells, setting them apart in the competitive landscape of the biotechnology industry. Aldagen's commitment to scientific excellence and patient-centric solutions has positioned it as a leader in the field, with notable achievements in clinical research and partnerships that enhance its market presence.
How does Aldagen, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Aldagen, Inc.'s score of 23 is lower than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Aldagen, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of figures in the latest emissions report. This includes a lack of detailed information on Scope 1, 2, or 3 emissions. Furthermore, there are no documented reduction targets or climate pledges available for the company. It is important to note that Aldagen, Inc. is a current subsidiary and may inherit emissions data and climate commitments from its parent organisation. However, no specific details regarding such cascaded data or initiatives from the parent company have been provided. As the company continues to develop its sustainability strategy, stakeholders may look forward to future disclosures that outline its carbon footprint and climate commitments.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Aldagen, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
